Two clinical trials found that reduced doses of GLP-1 weight-loss medications and newer oral pills such as Foundayo can maintain weight loss outcomes while lowering costs and side effects.
Participants who stepped down from higher doses retained much of their weight reduction over trial periods compared with controls. Oral formulations showed promise for patients who prefer pills over injections.
Endocrinologists said dose tapering strategies could expand access if insurers cover maintenance regimens. Gastrointestinal side effects, a common reason for discontinuation, were less frequent at lower doses in the studies.
Pharmaceutical companies are competing in a rapidly growing obesity therapeutics market. Regulators will review long-term safety data before approving widespread tapering protocols outside trial settings.
Public health experts cautioned that medication should complement diet and activity counseling. The trials did not examine all comorbid conditions, prompting calls for diverse enrollment in follow-up research.
Clinical trials found lower GLP-1 doses and oral pills such as Foundayo can maintain weight loss with reduced cost and side effects. Endocrinologists said taper strategies could expand access if insurers cover maintenance regimens.
Insurance formularies have not yet standardized coverage for lower-dose maintenance regimens described in the trials. Patient groups asked manufacturers to publish price comparisons for oral alternatives.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.medicalnewstoday.com/news